CD79A and infection: When experiencing infection, only 1 out of 16 pwMS under anti-CD20 developed quantitatively measurable IgG anti-nucleocapsid, 4 out of 16 developed IgG/IgM/IgA anti-nucleocapsid, and, at a later time point, 2 out of 14 developed IgG anti-nucleocapsid while 1 out of 14 developed IgG/IgM/IgA anti-nucleocapsid.